Ultralife (NASDAQ: ULBI) shares plunged 20.86% in Thursday’s pre-market trading, dropping to $6.46 from a previous close of $8.16.
The sharp decline follows Q2 2025 results that missed expectations, with revenue at $48.56 million and adjusted EPS of $0.07, both below analyst forecasts. Despite a 5.24% year-over-year revenue increase, earnings per share dropped 68%, driving the selloff.
